# ![@ThePharmaLetter Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::71542880.png) @ThePharmaLetter The Pharma Letter

The Pharma Letter posts on X about pharma, novartis, $abbv, sanofi the most. They currently have [------] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::71542880/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:interactions.svg)

- [--] Week [-----] -13%
- [--] Month [-----] +24%
- [--] Months [------] +158%
- [--] Year [------] +68%

### Mentions: [--] [#](/creator/twitter::71542880/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:posts_active.svg)

- [--] Month [--] -61%
- [--] Months [---] +113%
- [--] Year [---] +54%

### Followers: [------] [#](/creator/twitter::71542880/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:followers.svg)

- [--] Week [------] +0.04%
- [--] Month [------] +0.16%
- [--] Months [------] +0.88%
- [--] Year [------] +2.30%

### CreatorRank: [---------] [#](/creator/twitter::71542880/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::71542880/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [finance](/list/finance)  [countries](/list/countries)  [travel destinations](/list/travel-destinations)  [technology brands](/list/technology-brands)  [exchanges](/list/exchanges)  [vc firms](/list/vc-firms)  [automotive brands](/list/automotive-brands)  [financial services](/list/financial-services)  [currencies](/list/currencies) 

**Social topic influence**
[pharma](/topic/pharma), [novartis](/topic/novartis), [$abbv](/topic/$abbv), [sanofi](/topic/sanofi), [china](/topic/china), [ipo](/topic/ipo), [japan](/topic/japan), [gilead sciences](/topic/gilead-sciences), [acquisition](/topic/acquisition), [approval](/topic/approval)

**Top accounts mentioned or mentioned by**
[@novonordisk](/creator/undefined) [@novartis](/creator/undefined) [@abbvie](/creator/undefined) [@astrazeneca](/creator/undefined) [@sanofi](/creator/undefined) [@merck](/creator/undefined) [@gileadsciences](/creator/undefined) [@amgen](/creator/undefined) [@novonordisks](/creator/undefined) [@abbvies](/creator/undefined) [@genmab](/creator/undefined) [@sanofis](/creator/undefined) [@pfizer](/creator/undefined) [@nxerapharma](/creator/undefined) [@elilillyandco](/creator/undefined) [@astrazenecas](/creator/undefined) [@regeneron](/creator/undefined) [@eisaius](/creator/undefined) [@gsk](/creator/undefined) [@celltrioninc](/creator/undefined)

**Top assets mentioned**
[Novartis AG (NVS)](/topic/novartis) [AbbVie Inc (ABBV)](/topic/$abbv) [Sanofi (SNY)](/topic/sanofi) [Gilead Sciences, Inc. (GILD)](/topic/gilead-sciences) [Merck & Co., Inc. (MRK)](/topic/merck) [Pfizer, Inc. (PFE)](/topic/pfizer) [AstraZeneca PLC (AZN)](/topic/astrazeneca) [Caris Life Sciences, Inc. (CAI)](/topic/caris-life-sciences) [Trinity Capital Inc. (TRIN)](/topic/$trin) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [HCW Biologics Inc. (HCWB)](/topic/$hcwb) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Rain Oncology Inc (RAIN)](/topic/rain-oncology)
### Top Social Posts
Top posts by engagements in the last [--] hours

"@KitePharma and @arcellx advance anito-cel multiple myeloma program https://www.thepharmaletter.com/article/kite-and-arcellx-advance-anito-cel-multiple-myeloma-program https://www.thepharmaletter.com/article/kite-and-arcellx-advance-anito-cel-multiple-myeloma-program"  
[X Link](https://x.com/ThePharmaLetter/status/1790065803368259823)  2024-05-13T17:05Z 25.3K followers, [--] engagements


"550 jobs to go at EUROAPI as part of new Sanofi deal https://www.thepharmaletter.com/550-jobs-to-go-at-euroapi-as-part-of-new-sanofi-deal https://www.thepharmaletter.com/550-jobs-to-go-at-euroapi-as-part-of-new-sanofi-deal"  
[X Link](https://x.com/ThePharmaLetter/status/1807706399629078971)  2024-07-01T09:22Z 25.3K followers, [---] engagements


"@BicaraTx raises $362 million in Nasdaq debut https://www.thepharmaletter.com/biotechnology/bicara-therapeutics-raises-362-million-dollars-in-nasdaq-debut https://www.thepharmaletter.com/biotechnology/bicara-therapeutics-raises-362-million-dollars-in-nasdaq-debut"  
[X Link](https://x.com/ThePharmaLetter/status/1836062856585879663)  2024-09-17T15:21Z 25.3K followers, [--] engagements


"Exciva raises $59 million in Series B funding https://www.thepharmaletter.com/biotech-news/exciva-raises-59-million-in-series-b-funding https://www.thepharmaletter.com/biotech-news/exciva-raises-59-million-in-series-b-funding"  
[X Link](https://x.com/ThePharmaLetter/status/2013628163700515045)  2026-01-20T15:02Z 25.3K followers, [--] engagements


"@aspectbiosys and @novonordisk update on diabetes partnership https://www.thepharmaletter.com/pharma-news/aspect-biosystems-and-novo-nordisk-update-on-diabetes-partnership https://www.thepharmaletter.com/pharma-news/aspect-biosystems-and-novo-nordisk-update-on-diabetes-partnership"  
[X Link](https://x.com/ThePharmaLetter/status/2013898923773952479)  2026-01-21T08:58Z 25.4K followers, [--] engagements


"Advicenne gains marketing approval and reimbursement for Sibnayal in UAE https://www.thepharmaletter.com/biotech-news/advicenne-gains-marketing-approval-and-reimbursement-for-sibnayal-in-uae https://www.thepharmaletter.com/biotech-news/advicenne-gains-marketing-approval-and-reimbursement-for-sibnayal-in-uae"  
[X Link](https://x.com/ThePharmaLetter/status/2016160147182145876)  2026-01-27T14:43Z 25.3K followers, [---] engagements


"@intelliatx shares leap as FDA lifts trial hold https://www.thepharmaletter.com/biotech-news/intellia-shares-leap-as-fda-lifts-trial-hold https://www.thepharmaletter.com/biotech-news/intellia-shares-leap-as-fda-lifts-trial-hold"  
[X Link](https://x.com/ThePharmaLetter/status/2016446598025195794)  2026-01-28T09:41Z 25.3K followers, [--] engagements


"@antheiabio closes Series C to strengthen US drug production https://www.thepharmaletter.com/pharma-news/antheia-closes-series-c-to-strengthen-us-drug-production https://www.thepharmaletter.com/pharma-news/antheia-closes-series-c-to-strengthen-us-drug-production"  
[X Link](https://x.com/ThePharmaLetter/status/2016447028406915407)  2026-01-28T09:43Z 25.3K followers, [--] engagements


"FDA accepts Otsukas centanafadine NDA for priority review https://www.thepharmaletter.com/pharma-news/fda-accepts-otsuka-s-centanafadine-nda-for-priority-review https://www.thepharmaletter.com/pharma-news/fda-accepts-otsuka-s-centanafadine-nda-for-priority-review"  
[X Link](https://x.com/ThePharmaLetter/status/2016447083708850514)  2026-01-28T09:43Z 25.3K followers, [---] engagements


"Global expansion of @Idorsias Quviviq continues https://www.thepharmaletter.com/pharma-news/global-expansion-of-idorsia-s-quviviq-continues https://www.thepharmaletter.com/pharma-news/global-expansion-of-idorsia-s-quviviq-continues"  
[X Link](https://x.com/ThePharmaLetter/status/2016793398770884664)  2026-01-29T08:39Z 25.3K followers, [---] engagements


"@AstraZeneca commits $15 billion to China expansion strategy https://www.thepharmaletter.com/pharma-news/astrazeneca-commits-15bn-to-china-expansion-through-2030 https://www.thepharmaletter.com/pharma-news/astrazeneca-commits-15bn-to-china-expansion-through-2030"  
[X Link](https://x.com/ThePharmaLetter/status/2016910108177924336)  2026-01-29T16:23Z 25.3K followers, [--] engagements


"Dupixent delivers for @sanofi again https://www.thepharmaletter.com/pharma-news/dupixent-delivers-for-sanofi-again https://www.thepharmaletter.com/pharma-news/dupixent-delivers-for-sanofi-again"  
[X Link](https://x.com/ThePharmaLetter/status/2016910312289485272)  2026-01-29T16:24Z 25.4K followers, [--] engagements


"@Amgen wins EC approval for Uplizna in gMG https://www.thepharmaletter.com/biotech-news/amgen-wins-ec-approval-for-uplizna-in-gmg https://www.thepharmaletter.com/biotech-news/amgen-wins-ec-approval-for-uplizna-in-gmg"  
[X Link](https://x.com/ThePharmaLetter/status/2022324576244416747)  2026-02-13T14:58Z 25.4K followers, [--] engagements


". @Orphazyme_AS raises funds for arimoclomol filings in USA and Europe #biotech https://www.thepharmaletter.com/article/orphazyme-raises-funds-for-arimoclomol-filings-in-usa-and-europe https://www.thepharmaletter.com/article/orphazyme-raises-funds-for-arimoclomol-filings-in-usa-and-europe"  
[X Link](https://x.com/ThePharmaLetter/status/1225819054889488385)  2020-02-07T16:30Z 25.4K followers, [--] engagements


"@AstraZeneca expands cardiorenal portfolio snapping up @cincorpharma https://www.thepharmaletter.com/article/astrazeneca-expands-cardiorenal-portfolio-snapping-up-cincor-pharma https://www.thepharmaletter.com/article/astrazeneca-expands-cardiorenal-portfolio-snapping-up-cincor-pharma"  
[X Link](https://x.com/ThePharmaLetter/status/1612747592114343936)  2023-01-10T09:46Z 25.4K followers, [--] engagements


"Leaps by Bayer co-leads $100 million @BoundlessBio financing https://www.thepharmaletter.com/article/leaps-by-bayer-co-leads-100-million-boundless-bio-financing https://www.thepharmaletter.com/article/leaps-by-bayer-co-leads-100-million-boundless-bio-financing"  
[X Link](https://x.com/ThePharmaLetter/status/1658782937989390337)  2023-05-17T10:34Z 25.4K followers, [---] engagements


"@PhrmMar and Luye Pharmas NDA for lurbinectedin accepted in China https://www.thepharmaletter.com/article/pharmamar-and-luye-pharma-s-nda-for-lurbinectedin-accepted-in-china https://www.thepharmaletter.com/article/pharmamar-and-luye-pharma-s-nda-for-lurbinectedin-accepted-in-china"  
[X Link](https://x.com/ThePharmaLetter/status/1668904980403695620)  2023-06-14T08:55Z 25.4K followers, [---] engagements


"Mass layoff signals turbulent time for Kinnate Biopharma https://www.thepharmaletter.com/article/mass-layoff-signals-turbulent-time-for-kinnate-biopharma https://www.thepharmaletter.com/article/mass-layoff-signals-turbulent-time-for-kinnate-biopharma"  
[X Link](https://x.com/ThePharmaLetter/status/1704768681220170064)  2023-09-21T08:05Z 25.4K followers, [---] engagements


"@PharmaEssentia looks to broaden focus with checkpoint blocker deal https://www.thepharmaletter.com/article/pharmaessentia-looks-to-broaden-interests-with-checkpoint-blocker-deal https://www.thepharmaletter.com/article/pharmaessentia-looks-to-broaden-interests-with-checkpoint-blocker-deal"  
[X Link](https://x.com/ThePharmaLetter/status/1711464292040507784)  2023-10-09T19:30Z 25.4K followers, [---] engagements


"Vaccitech rebrands as @BarinthusBio https://www.thepharmaletter.com/article/vaccitech-rebrands-as-barinthus-biotherapeutics https://www.thepharmaletter.com/article/vaccitech-rebrands-as-barinthus-biotherapeutics"  
[X Link](https://x.com/ThePharmaLetter/status/1722204607798223125)  2023-11-08T10:49Z 25.4K followers, [---] engagements


"Ono inks drug discovery deal with Shattuck Labs https://www.thepharmaletter.com/article/ono-inks-drug-discovery-deal-with-shattuck-labs https://www.thepharmaletter.com/article/ono-inks-drug-discovery-deal-with-shattuck-labs"  
[X Link](https://x.com/ThePharmaLetter/status/1757701561759744184)  2024-02-14T09:41Z 25.4K followers, [---] engagements


"Caris Life Sciences partners with Merck KGaA on ADCs https://www.thepharmaletter.com/article/caris-life-sciences-partners-with-merck-kgaa-on-adcs https://www.thepharmaletter.com/article/caris-life-sciences-partners-with-merck-kgaa-on-adcs"  
[X Link](https://x.com/ThePharmaLetter/status/1776235785999528045)  2024-04-05T13:09Z 25.4K followers, [---] engagements


"@MazeInBiotech finds new partner for Pompe disease candidate https://www.thepharmaletter.com/article/maze-therapeutics-finds-new-partner-for-pompe-disease-candidate https://www.thepharmaletter.com/article/maze-therapeutics-finds-new-partner-for-pompe-disease-candidate"  
[X Link](https://x.com/ThePharmaLetter/status/1790066129894776876)  2024-05-13T17:06Z 25.4K followers, [--] engagements


"Connect Biopharma strengthens leadership team https://www.thepharmaletter.com/article/connect-biopharma-strengthens-leadership-team https://www.thepharmaletter.com/article/connect-biopharma-strengthens-leadership-team"  
[X Link](https://x.com/ThePharmaLetter/status/1802622195505492428)  2024-06-17T08:39Z 25.4K followers, [---] engagements


"@UpstreamBio goes public amid spate of IPOs https://www.thepharmaletter.com/biotechnology/upstream-bio-goes-public-amid-spate-of-ipos https://www.thepharmaletter.com/biotechnology/upstream-bio-goes-public-amid-spate-of-ipos"  
[X Link](https://x.com/ThePharmaLetter/status/1837031765908525482)  2024-09-20T07:31Z 25.4K followers, [--] engagements


"Shattuck Labs cuts workforce and shifts focus https://www.thepharmaletter.com/biotechnology/shattuck-labs-cuts-workforce-and-shifts-focus https://www.thepharmaletter.com/biotechnology/shattuck-labs-cuts-workforce-and-shifts-focus"  
[X Link](https://x.com/ThePharmaLetter/status/1841757010590675177)  2024-10-03T08:27Z 25.4K followers, [---] engagements


"Former Mirati CMO Alan Sandler joins @AlxOncology https://www.thepharmaletter.com/former-mirati-cmo-alan-sandler-joins-alx-oncology https://www.thepharmaletter.com/former-mirati-cmo-alan-sandler-joins-alx-oncology"  
[X Link](https://x.com/ThePharmaLetter/status/1857361764179964202)  2024-11-15T09:55Z 25.4K followers, [---] engagements


"@ALXOncology says evorpacept scores well in Phase II study https://www.thepharmaletter.com/alx-oncology-says-evorpacept-scores-well-in-phase-2-study https://www.thepharmaletter.com/alx-oncology-says-evorpacept-scores-well-in-phase-2-study"  
[X Link](https://x.com/ThePharmaLetter/status/1883797542800109941)  2025-01-27T08:41Z 25.4K followers, [--] engagements


"Third Harmonic and Inventiva slash workforces https://www.thepharmaletter.com/biotechnology/third-harmonic-bio-and-inventiva-slash-workforces https://www.thepharmaletter.com/biotechnology/third-harmonic-bio-and-inventiva-slash-workforces"  
[X Link](https://x.com/ThePharmaLetter/status/1889712410824425573)  2025-02-12T16:25Z 25.4K followers, [---] engagements


"@Septerna_Inc sinks as it discontinues lead asset SEP-786 https://www.thepharmaletter.com/septerna-sinks-as-it-discontinues-lead-asset-seo-786 https://www.thepharmaletter.com/septerna-sinks-as-it-discontinues-lead-asset-seo-786"  
[X Link](https://x.com/ThePharmaLetter/status/1892497949206192172)  2025-02-20T08:54Z 25.4K followers, [--] engagements


"@sanofi to expand CNS pipeline with buy of @VigilNeuro https://www.thepharmaletter.com/sanofi-to-expand-cns-pipeline-with-buy-of-vigil-neuroscience https://www.thepharmaletter.com/sanofi-to-expand-cns-pipeline-with-buy-of-vigil-neuroscience"  
[X Link](https://x.com/ThePharmaLetter/status/1925822307596914763)  2025-05-23T07:53Z 25.4K followers, [--] engagements


"@PharmaEssentia eyes expanded US use of Besremi after positive Phase III data https://www.thepharmaletter.com/biotechnology/pharmaessentia-besremi-phase-iii https://www.thepharmaletter.com/biotechnology/pharmaessentia-besremi-phase-iii"  
[X Link](https://x.com/ThePharmaLetter/status/1930602087546507538)  2025-06-05T12:26Z 25.4K followers, [--] engagements


"@EliLillyandCo to acquire @VerveTx https://www.thepharmaletter.com/biotechnology/lilly-to-acquire-verve-therapeutics https://www.thepharmaletter.com/biotechnology/lilly-to-acquire-verve-therapeutics"  
[X Link](https://x.com/ThePharmaLetter/status/1935258394681606555)  2025-06-18T08:48Z 25.4K followers, [--] engagements


"Nasus Pharma prices $10 million IPO https://www.thepharmaletter.com/pharmaceutical/nasus-pharma-prices-10-million-ipo https://www.thepharmaletter.com/pharmaceutical/nasus-pharma-prices-10-million-ipo"  
[X Link](https://x.com/ThePharmaLetter/status/1956269950051471614)  2025-08-15T08:21Z 25.4K followers, [---] engagements


"@Novartis to acquire @TourmalineBio https://www.thepharmaletter.com/biotechnology/novartis-to-acquire-tourmaline-bio https://www.thepharmaletter.com/biotechnology/novartis-to-acquire-tourmaline-bio"  
[X Link](https://x.com/ThePharmaLetter/status/1965809543805599983)  2025-09-10T16:08Z 25.4K followers, [--] engagements


"@BarinthusBio to merge with Clywedog https://www.thepharmaletter.com/biotechnology/barinthus-biotherapeutics-to-merge-with-clywedog https://www.thepharmaletter.com/biotechnology/barinthus-biotherapeutics-to-merge-with-clywedog"  
[X Link](https://x.com/ThePharmaLetter/status/1974022759891018161)  2025-10-03T08:04Z 25.4K followers, [--] engagements


"@hikmapharma and @Celltrioninc expand biosimilars access in MENA https://www.thepharmaletter.com/biosimilars/hikma-and-celltrion-expand-biosimilars-access-in-mena https://www.thepharmaletter.com/biosimilars/hikma-and-celltrion-expand-biosimilars-access-in-mena"  
[X Link](https://x.com/ThePharmaLetter/status/1975580881633894693)  2025-10-07T15:16Z 25.4K followers, [--] engagements


"@Celltrioninc presents positive RWE on switching from IV to SC infliximab https://www.thepharmaletter.com/biosimilars/celltrion-presents-positive-rwe-on-switching-from-iv-to-sc-infliximab https://www.thepharmaletter.com/biosimilars/celltrion-presents-positive-rwe-on-switching-from-iv-to-sc-infliximab"  
[X Link](https://x.com/ThePharmaLetter/status/1975581046767759483)  2025-10-07T15:16Z 25.4K followers, [--] engagements


"@CandelTx secures $130 million loan facility with Trinity Capital https://www.thepharmaletter.com/biotechnology/candel-thera-secures-130-million-loan-facility-with-trinity-capital https://www.thepharmaletter.com/biotechnology/candel-thera-secures-130-million-loan-facility-with-trinity-capital"  
[X Link](https://x.com/ThePharmaLetter/status/1978778542923030707)  2025-10-16T11:02Z 25.4K followers, [--] engagements


"XOMA to buy struggling @generationbio https://www.thepharmaletter.com/biotechnology/xoma-to-buy-struggling-generation-bio https://www.thepharmaletter.com/biotechnology/xoma-to-buy-struggling-generation-bio"  
[X Link](https://x.com/ThePharmaLetter/status/2000964292095422488)  2025-12-16T16:20Z 25.4K followers, [--] engagements


"@CencoraGlobal to fast-track @OneOncology buyout in $7.4bn deal https://www.thepharmaletter.com/pharmaceutical/cencora-to-fasttrack-oneoncology-buyout-in-74bn-deal https://www.thepharmaletter.com/pharmaceutical/cencora-to-fasttrack-oneoncology-buyout-in-74bn-deal"  
[X Link](https://x.com/ThePharmaLetter/status/2001651288485040134)  2025-12-18T13:50Z 25.4K followers, [--] engagements


"@Genmab to discontinue clinical development of acasunlimab https://www.thepharmaletter.com/biotechnology/genmab-to-discontinue-clinical-development-of-acasunlimab https://www.thepharmaletter.com/biotechnology/genmab-to-discontinue-clinical-development-of-acasunlimab"  
[X Link](https://x.com/ThePharmaLetter/status/2006051597160247443)  2025-12-30T17:15Z 25.4K followers, [--] engagements


"Prospects for @REGENXBIO's clemidsogene lanparvovec approval in Hunter syndrome https://www.thepharmaletter.com/biotechnology/prospects-for-regenxbio-s-clemidsogene-lanparvovec-approval-in-hunter-syndrome https://www.thepharmaletter.com/biotechnology/prospects-for-regenxbio-s-clemidsogene-lanparvovec-approval-in-hunter-syndrome"  
[X Link](https://x.com/ThePharmaLetter/status/2007036519115379000)  2026-01-02T10:29Z 25.4K followers, [---] engagements


"@QimingVCs @InSilicoMeds successfully lists on HKEX https://www.thepharmaletter.com/pharmaceutical/qiming-venture-partners-insilico-medicine-successfully-lists-on-hkex https://www.thepharmaletter.com/pharmaceutical/qiming-venture-partners-insilico-medicine-successfully-lists-on-hkex"  
[X Link](https://x.com/ThePharmaLetter/status/2007125644401103045)  2026-01-02T16:23Z 25.4K followers, [---] engagements


"@StructureTx signs patent deal with @genentech https://www.thepharmaletter.com/pharmaceutical/structure-therapeutics-signs-patent-deal-with-genentech https://www.thepharmaletter.com/pharmaceutical/structure-therapeutics-signs-patent-deal-with-genentech"  
[X Link](https://x.com/ThePharmaLetter/status/2008558912346484849)  2026-01-06T15:18Z 25.4K followers, [--] engagements


"ProBioGen and Zag Bio forge strategic CMC partnership https://www.thepharmaletter.com/biotechnology/probiogen-and-zag-bio-forge-strategic-cmc-partnership https://www.thepharmaletter.com/biotechnology/probiogen-and-zag-bio-forge-strategic-cmc-partnership"  
[X Link](https://x.com/ThePharmaLetter/status/2008904896754459051)  2026-01-07T14:13Z 25.4K followers, [--] engagements


"@Genmab selects @AnthropicAI for AI-powered programs https://www.thepharmaletter.com/biotech-news/genmab-selects-anthropic-for-ai-powered-programs https://www.thepharmaletter.com/biotech-news/genmab-selects-anthropic-for-ai-powered-programs"  
[X Link](https://x.com/ThePharmaLetter/status/2009250178637672931)  2026-01-08T13:05Z 25.4K followers, [--] engagements


"@EliLillyandCo confirms bid to acquire Ventyx Biosciences https://www.thepharmaletter.com/biotech-news/lilly-confirms-bid-to-acquire-ventyx-biosciences https://www.thepharmaletter.com/biotech-news/lilly-confirms-bid-to-acquire-ventyx-biosciences"  
[X Link](https://x.com/ThePharmaLetter/status/2009251815762637098)  2026-01-08T13:12Z 25.4K followers, [--] engagements


"@PharmaEssentia's sBLA in essential thrombocythemia accepted by FDA https://www.thepharmaletter.com/biotech-news/pharmaessentia-s-sbla-in-essential-thrombocythemia-accepted-by-fda https://www.thepharmaletter.com/biotech-news/pharmaessentia-s-sbla-in-essential-thrombocythemia-accepted-by-fda"  
[X Link](https://x.com/ThePharmaLetter/status/2011357692112294100)  2026-01-14T08:40Z 25.4K followers, [--] engagements


"Tribunal upholds Ipsens termination of R&D agreement with Galderma https://www.thepharmaletter.com/pharma-news/tribunal-upholds-ipsen-s-termination-of-r-and-d-agreement-with-galderma https://www.thepharmaletter.com/pharma-news/tribunal-upholds-ipsen-s-termination-of-r-and-d-agreement-with-galderma"  
[X Link](https://x.com/ThePharmaLetter/status/2014629855715803290)  2026-01-23T09:22Z 25.4K followers, [---] engagements


"Ocular Therapeutix (@OCUTX) names David Robinson as global CCO https://www.thepharmaletter.com/pharma-news/ocular-therapeutix-names-david-robinson-as-global-cco https://www.thepharmaletter.com/pharma-news/ocular-therapeutix-names-david-robinson-as-global-cco"  
[X Link](https://x.com/ThePharmaLetter/status/2014630100919112108)  2026-01-23T09:23Z 25.4K followers, [---] engagements


"SK bioscience advancing Zaire ebolavirus vaccine in CEPI and Merck & Co collab https://www.thepharmaletter.com/pharma-news/sk-bioscience-advancing-zaire-ebolavirus-vaccine-in-cepi-and-merck-co-collab https://www.thepharmaletter.com/pharma-news/sk-bioscience-advancing-zaire-ebolavirus-vaccine-in-cepi-and-merck-co-collab"  
[X Link](https://x.com/ThePharmaLetter/status/2014630301306159264)  2026-01-23T09:24Z 25.4K followers, [---] engagements


"@GileadSciences publishes Trodelvy-Keytruda data in NEJM https://www.thepharmaletter.com/biotech-news/gilead-sciences-publishes-trodelvykeytruda-data-in-nejm https://www.thepharmaletter.com/biotech-news/gilead-sciences-publishes-trodelvykeytruda-data-in-nejm"  
[X Link](https://x.com/ThePharmaLetter/status/2014630605527388435)  2026-01-23T09:25Z 25.4K followers, [--] engagements


"@GileadSciences' Trodelvy added to NCCN guidelines https://www.thepharmaletter.com/biotech-news/gilead-s-trodelvy-added-to-nccn-guidelines https://www.thepharmaletter.com/biotech-news/gilead-s-trodelvy-added-to-nccn-guidelines"  
[X Link](https://x.com/ThePharmaLetter/status/2016795341622837573)  2026-01-29T08:47Z 25.4K followers, [--] engagements


"Hanmi expands efpeglenatide reach with Mexico distribution deal https://www.thepharmaletter.com/biotech-news/hanmi-expands-efpeglenatide-reach-with-mexico-distribution-deal https://www.thepharmaletter.com/biotech-news/hanmi-expands-efpeglenatide-reach-with-mexico-distribution-deal"  
[X Link](https://x.com/ThePharmaLetter/status/2016795993786778001)  2026-01-29T08:50Z 25.4K followers, [---] engagements


"Takeda lifts guidance as growth brands offset Vyvanse drag https://www.thepharmaletter.com/pharma-news/takeda-lifts-guidance-as-growth-brands-offset-vyvanse-drag https://www.thepharmaletter.com/pharma-news/takeda-lifts-guidance-as-growth-brands-offset-vyvanse-drag"  
[X Link](https://x.com/ThePharmaLetter/status/2016909688198029421)  2026-01-29T16:21Z 25.4K followers, [--] engagements


"Revenue falls for @pfizer while non-COVID growth offsets decline https://www.thepharmaletter.com/pharma-news/revenue-falls-for-pfizer-while-noncovid-growth-offsets-decline https://www.thepharmaletter.com/pharma-news/revenue-falls-for-pfizer-while-noncovid-growth-offsets-decline"  
[X Link](https://x.com/ThePharmaLetter/status/2019005371223007626)  2026-02-04T11:09Z 25.4K followers, [---] engagements


"@Amgen posts double-digit revenue and EPS growth for [----] https://www.thepharmaletter.com/biotech-news/amgen-posts-double-digit-revenue-and-eps-growth-for-2025 https://www.thepharmaletter.com/biotech-news/amgen-posts-double-digit-revenue-and-eps-growth-for-2025"  
[X Link](https://x.com/ThePharmaLetter/status/2019077519899525588)  2026-02-04T15:56Z 25.4K followers, [--] engagements


"FTC and Express Scripts agree deal promised to lower drug costs #FTC #ExpressScripts #DrugCosts #PBMs #HealthcarePolicy #PrescriptionDrugs #DrugPricing #Competition #USHealthcare #PharmaNews #HealthEconomics #Regulation https://www.thepharmaletter.com/pharma-news/ftc-and-express-scripts-agree-deal-promised-to-lower-drug-costs https://www.thepharmaletter.com/pharma-news/ftc-and-express-scripts-agree-deal-promised-to-lower-drug-costs"  
[X Link](https://x.com/ThePharmaLetter/status/2019479293948989526)  2026-02-05T18:32Z 25.4K followers, [---] engagements


"HHS drops 340B rebate pilot after court setback https://www.thepharmaletter.com/pharma-news/hhs-drops-340b-rebate-pilot-after-court-setback https://www.thepharmaletter.com/pharma-news/hhs-drops-340b-rebate-pilot-after-court-setback"  
[X Link](https://x.com/ThePharmaLetter/status/2020880887156486238)  2026-02-09T15:22Z 25.4K followers, [---] engagements


"@sanofi's rilzabrutinib wins Breakthrough status from FDA for wAIHA https://www.thepharmaletter.com/sanofi-s-rilzabrutinib-wins-breakthrough-status-from-fda-for-waiha https://www.thepharmaletter.com/sanofi-s-rilzabrutinib-wins-breakthrough-status-from-fda-for-waiha"  
[X Link](https://x.com/ThePharmaLetter/status/2020963203019309403)  2026-02-09T20:49Z 25.4K followers, [--] engagements


"Pandorum Technologies raises $18 million in Series B financing https://www.thepharmaletter.com/biotech-news/pandorum-technologies-raises-18-million-in-series-b-financing https://www.thepharmaletter.com/biotech-news/pandorum-technologies-raises-18-million-in-series-b-financing"  
[X Link](https://x.com/ThePharmaLetter/status/2021249789921206434)  2026-02-10T15:47Z 25.4K followers, [--] engagements


"US FDA rejection sends @REGENXBIO shares sharply lower https://www.thepharmaletter.com/biotech-news/us-fda-rejection-sends-regenxbio-shares-sharply-lower https://www.thepharmaletter.com/biotech-news/us-fda-rejection-sends-regenxbio-shares-sharply-lower"  
[X Link](https://x.com/ThePharmaLetter/status/2021250248149017087)  2026-02-10T15:49Z 25.4K followers, [---] engagements


"Sanofi Ventures co-leads $85 million QuantX series B https://www.thepharmaletter.com/pharma-news/sanofi-ventures-co-leads-85-million-quantx-series-b https://www.thepharmaletter.com/pharma-news/sanofi-ventures-co-leads-85-million-quantx-series-b"  
[X Link](https://x.com/ThePharmaLetter/status/2021250675657609688)  2026-02-10T15:51Z 25.4K followers, [--] engagements


"@AstraZenecas Imfinzi wins NICE nod as first perioperative IO treatment for MIBC https://www.thepharmaletter.com/biotech-news/astrazeneca-s-imfinzi-wins-nice-nod-as-first-perioperative-io-treatment-for-mibc https://www.thepharmaletter.com/biotech-news/astrazeneca-s-imfinzi-wins-nice-nod-as-first-perioperative-io-treatment-for-mibc"  
[X Link](https://x.com/ThePharmaLetter/status/2021283836521308453)  2026-02-10T18:03Z 25.4K followers, [--] engagements


"@GileadSciences 4th-qtr beats expectations but guidance disappoints https://www.thepharmaletter.com/pharma-news/gilead-sciences-4th-qtr-beats-expectations-but-guidance-disappoints https://www.thepharmaletter.com/pharma-news/gilead-sciences-4th-qtr-beats-expectations-but-guidance-disappoints"  
[X Link](https://x.com/ThePharmaLetter/status/2021580921569247339)  2026-02-11T13:43Z 25.4K followers, [--] engagements


"@FujifilmHCUK opens $500 million UK biologics facility https://www.thepharmaletter.com/biotech-news/fujifilm-opens-500-million-uk-biologics-expansion-in-teesside https://www.thepharmaletter.com/biotech-news/fujifilm-opens-500-million-uk-biologics-expansion-in-teesside"  
[X Link](https://x.com/ThePharmaLetter/status/2021581013202116905)  2026-02-11T13:44Z 25.4K followers, [--] engagements


"Today's #companyspotlight is @BarinthusBio a clinical-stage biopharma company developing novel T cell immunotherapeutic candidates. Find out more about the company here: https://www.thepharmaletter.com/company/barinthus-biotherapeutics https://www.thepharmaletter.com/company/barinthus-biotherapeutics"  
[X Link](https://x.com/ThePharmaLetter/status/1782813491432202399)  2024-04-23T16:47Z 25.4K followers, [---] engagements


"HCW Biologics takes aim at CD8+ in deal with WY Biotech https://www.thepharmaletter.com/biotechnology/hcw-biologics-takes-aim-at-cd8-in-deal-with-wy-biotech https://www.thepharmaletter.com/biotechnology/hcw-biologics-takes-aim-at-cd8-in-deal-with-wy-biotech"  
[X Link](https://x.com/ThePharmaLetter/status/1859914498372731016)  2024-11-22T10:59Z 25.4K followers, [---] engagements


"Metabolic focus steers Maze to bumper Series D haul https://www.thepharmaletter.com/pharmaceutical/maze-therapeutics-secures-115-million-in-series-d-financing https://www.thepharmaletter.com/pharmaceutical/maze-therapeutics-secures-115-million-in-series-d-financing"  
[X Link](https://x.com/ThePharmaLetter/status/1864598577856528888)  2024-12-05T09:11Z 25.4K followers, [---] engagements


"Shattuck Labs expects $103 million from private placing https://www.thepharmaletter.com/biotechnology/shattuck-labs-expects-103-million-from-private-placing https://www.thepharmaletter.com/biotechnology/shattuck-labs-expects-103-million-from-private-placing"  
[X Link](https://x.com/ThePharmaLetter/status/1953117163687977178)  2025-08-06T15:33Z 25.4K followers, [---] engagements


"@SOPHiAGENETICS collabs combine AI analytics with sequencing https://www.thepharmaletter.com/biotechnology/sophia-genetics-collabs-combine-ai-analytics-with-sequencing https://www.thepharmaletter.com/biotechnology/sophia-genetics-collabs-combine-ai-analytics-with-sequencing"  
[X Link](https://x.com/ThePharmaLetter/status/1988648788127527382)  2025-11-12T16:43Z 25.4K followers, [--] engagements


"LB Pharmaceuticals names Kaya Pai Panandiker as CCO https://www.thepharmaletter.com/biotechnology/lb-pharmaceuticals-nameskaya-pai-panandiker-as-cco https://www.thepharmaletter.com/biotechnology/lb-pharmaceuticals-nameskaya-pai-panandiker-as-cco"  
[X Link](https://x.com/ThePharmaLetter/status/1988649048270880947)  2025-11-12T16:44Z 25.4K followers, [---] engagements


"@Abingworthbio announces leadership transition and appointments https://www.thepharmaletter.com/pharmaceutical/abingworth-announces-leadership-transition-and-appointments https://www.thepharmaletter.com/pharmaceutical/abingworth-announces-leadership-transition-and-appointments"  
[X Link](https://x.com/ThePharmaLetter/status/2008199903177236843)  2026-01-05T15:32Z 25.4K followers, [--] engagements


"@hikmapharma launches denosumab biosimilars in USA https://www.thepharmaletter.com/biosimilars-news/hikma-launches-denosumab-biosimilars-in-usa https://www.thepharmaletter.com/biosimilars-news/hikma-launches-denosumab-biosimilars-in-usa"  
[X Link](https://x.com/ThePharmaLetter/status/2013585880326303928)  2026-01-20T12:14Z 25.4K followers, [--] engagements


"Sagebrush sues Amgen over 340B program row https://www.thepharmaletter.com/biotech-news/sagebrush-sues-amgen-over-340b-program-row https://www.thepharmaletter.com/biotech-news/sagebrush-sues-amgen-over-340b-program-row"  
[X Link](https://x.com/ThePharmaLetter/status/2014630753775001856)  2026-01-23T09:26Z 25.4K followers, [---] engagements


"Merck walks away from Revolution talks as price gap bites https://www.thepharmaletter.com/pharma-news/merck--co-walks-away-from-revolution-talks-as-price-gap-bites https://www.thepharmaletter.com/pharma-news/merck--co-walks-away-from-revolution-talks-as-price-gap-bites"  
[X Link](https://x.com/ThePharmaLetter/status/2016080319636509135)  2026-01-27T09:26Z 25.4K followers, [---] engagements


"@REGENXBIO shares hit by setback with gene therapies https://www.thepharmaletter.com/biotech-news/regenxbio-shares-hit-by-setback-with-gene-therapies https://www.thepharmaletter.com/biotech-news/regenxbio-shares-hit-by-setback-with-gene-therapies"  
[X Link](https://x.com/ThePharmaLetter/status/2016796093057528106)  2026-01-29T08:50Z 25.4K followers, [--] engagements


"@WuXiBiologics Sinorda team up on bispecific antibody for IBD https://www.thepharmaletter.com/biotech-news/wuxi-biologics-sinorda-team-up-on-bispecific-antibody-for-ibd https://www.thepharmaletter.com/biotech-news/wuxi-biologics-sinorda-team-up-on-bispecific-antibody-for-ibd"  
[X Link](https://x.com/ThePharmaLetter/status/2016909998916264407)  2026-01-29T16:23Z 25.4K followers, [--] engagements


"@WuXiBiologics licenses trispecific immune engager to @VertexPharma https://www.thepharmaletter.com/biotech-news/wuxi-biologics-licenses-trispecific-immune-engager-to-vertex https://www.thepharmaletter.com/biotech-news/wuxi-biologics-licenses-trispecific-immune-engager-to-vertex"  
[X Link](https://x.com/ThePharmaLetter/status/2018686288077955378)  2026-02-03T14:01Z 25.4K followers, [--] engagements


"UK backs Dupixent as first biologic for severe nasal polyps #Dupixent #Sanofi #Regeneron #Biologics #NasalPolyps #CRSwNP #ENT #Immunology #NHS #UKHealthcare #PharmaNews #DrugApproval #MarketAccess #Biotech #Healthcare https://www.thepharmaletter.com/biotech-news/uk-backs-dupilumab-as-first-biologic-for-severe-nasal-polyps https://www.thepharmaletter.com/biotech-news/uk-backs-dupilumab-as-first-biologic-for-severe-nasal-polyps"  
[X Link](https://x.com/ThePharmaLetter/status/2019477799749234706)  2026-02-05T18:26Z 25.4K followers, [---] engagements


"@abbvie shares slide on perceived Humira reliance #AbbVie #Humira #Biopharma #PharmaNews #EarningsReaction #Biosimilars #Immunology #HealthcareInvesting #StockMarket #PatentCliff #DrugPipeline #MarketSentiment https://www.thepharmaletter.com/pharma-news/abbvie-shares-slide-on-perceived-humira-reliance https://www.thepharmaletter.com/pharma-news/abbvie-shares-slide-on-perceived-humira-reliance"  
[X Link](https://x.com/ThePharmaLetter/status/2019478489406091265)  2026-02-05T18:29Z 25.4K followers, [--] engagements


"@AstraZeneca delivers continued growth toward $80 billion target https://www.thepharmaletter.com/pharma-news/astrazeneca-delivers-continued-growth-toward-80-billion-target https://www.thepharmaletter.com/pharma-news/astrazeneca-delivers-continued-growth-toward-80-billion-target"  
[X Link](https://x.com/ThePharmaLetter/status/2021250432090231138)  2026-02-10T15:50Z 25.4K followers, [--] engagements


"Novo Nordisk commences legal action against Hims & Hers https://www.thepharmaletter.com/pharma-news/novo-nordisk-commences-legal-action-against-hims-and-hers https://www.thepharmaletter.com/pharma-news/novo-nordisk-commences-legal-action-against-hims-and-hers"  
[X Link](https://x.com/ThePharmaLetter/status/2021284042205741445)  2026-02-10T18:04Z 25.4K followers, [---] engagements


"@UpstreamBio battered despite positive new verekitug data https://www.thepharmaletter.com/biotech-news/upstream-bio-battered-despite-positive-new-verekitug-data https://www.thepharmaletter.com/biotech-news/upstream-bio-battered-despite-positive-new-verekitug-data"  
[X Link](https://x.com/ThePharmaLetter/status/2021882777868587328)  2026-02-12T09:43Z 25.4K followers, [--] engagements


"Why global investors are turning to Egyptian pharma: a plant-level perspective from Zeta Pharma Egypt https://www.thepharmaletter.com/pharma-news/why-global-investors-are-turning-to-egyptian-pharma-a-plant-level-perspective-from-zeta-pharma-egypt https://www.thepharmaletter.com/pharma-news/why-global-investors-are-turning-to-egyptian-pharma-a-plant-level-perspective-from-zeta-pharma-egypt"  
[X Link](https://x.com/ThePharmaLetter/status/2021883195948691693)  2026-02-12T09:44Z 25.4K followers, [---] engagements


"Mercks Beln Garijo to become CEO of @sanofi https://www.thepharmaletter.com/pharma-news/merck-s-belen-garijo-to-become-ceo-of-sanofi https://www.thepharmaletter.com/pharma-news/merck-s-belen-garijo-to-become-ceo-of-sanofi"  
[X Link](https://x.com/ThePharmaLetter/status/2022323776252260607)  2026-02-13T14:55Z 25.4K followers, [---] engagements


"@DaiichiSankyoUS files for new Datroway indication in Japan https://www.thepharmaletter.com/biotech-news/daiichi-files-for-new-datroway-indication-in-japan https://www.thepharmaletter.com/biotech-news/daiichi-files-for-new-datroway-indication-in-japan"  
[X Link](https://x.com/ThePharmaLetter/status/2022324438876741990)  2026-02-13T14:58Z 25.4K followers, [--] engagements


"Sandoz confirms EC approval of Ondibta biosimilar https://www.thepharmaletter.com/biosimilars-news/sandoz-confirms-ec-approval-of-ondibta-biosimilar https://www.thepharmaletter.com/biosimilars-news/sandoz-confirms-ec-approval-of-ondibta-biosimilar"  
[X Link](https://x.com/ThePharmaLetter/status/2011732627204817236)  2026-01-15T09:30Z 25.4K followers, [---] engagements


"Bristol Myers posts modest Q4 growth outlines cautious outlook #BristolMyers #BMY #Q4Results #FY2025 #Earnings #PharmaNews #Biopharma #HealthcareInvesting #StockMarket #GrowthOutlook https://www.thepharmaletter.com/pharma-news/bristol-myers-posts-modest-q4-growth-outlines-cautious-outlook https://www.thepharmaletter.com/pharma-news/bristol-myers-posts-modest-q4-growth-outlines-cautious-outlook"  
[X Link](https://x.com/ThePharmaLetter/status/2019479873803215194)  2026-02-05T18:34Z 25.4K followers, [---] engagements


"@VerricaPharma appoints Chris Chapman as CCO https://www.thepharmaletter.com/pharma-news/verrica-pharma-appoints-chris-chapman-as-cco https://www.thepharmaletter.com/pharma-news/verrica-pharma-appoints-chris-chapman-as-cco"  
[X Link](https://x.com/ThePharmaLetter/status/2022324816796086371)  2026-02-13T14:59Z 25.4K followers, [--] engagements


"@Novartis Vanrafia Phase III data support slowing of kidney function decline in IgA nephropathy patients https://www.thepharmaletter.com/pharma-news/novartis-vanrafia-phase-iii-data-support-slowing-of-kidney-function-decline-in-iga-nephropathy-patients https://www.thepharmaletter.com/pharma-news/novartis-vanrafia-phase-iii-data-support-slowing-of-kidney-function-decline-in-iga-nephropathy-patients"  
[X Link](https://x.com/ThePharmaLetter/status/2022325106836430881)  2026-02-13T15:00Z 25.4K followers, [---] engagements


"Late-stage washout clouds outlook for Rain Oncology https://www.thepharmaletter.com/article/late-stage-trial-flop-clouds-outlook-for-rain-oncology https://www.thepharmaletter.com/article/late-stage-trial-flop-clouds-outlook-for-rain-oncology"  
[X Link](https://x.com/ThePharmaLetter/status/1661015068748943361)  2023-05-23T14:23Z 25.4K followers, [---] engagements


"@EliLillyandCo punts $2.4 billion on DICE Therapeutics https://www.thepharmaletter.com/article/lilly-punts-2-4-billion-on-dice-therapeutics https://www.thepharmaletter.com/article/lilly-punts-2-4-billion-on-dice-therapeutics"  
[X Link](https://x.com/ThePharmaLetter/status/1671470438629736449)  2023-06-21T10:49Z 25.4K followers, [--] engagements


"SK bioscience signs MoU with Thai government company on vaccines https://www.thepharmaletter.com/article/sk-bioscience-signs-mou-with-thai-government-company-on-vaccines https://www.thepharmaletter.com/article/sk-bioscience-signs-mou-with-thai-government-company-on-vaccines"  
[X Link](https://x.com/ThePharmaLetter/status/1676610491177639939)  2023-07-05T15:14Z 25.4K followers, [---] engagements


"SK bioscience and Vaxxas to develop needle-free patch delivery of typhoid vaccine https://www.thepharmaletter.com/article/sk-bioscience-and-vaxxas-to-develop-needle-free-patch-delivery-of-typhoid-vaccine https://www.thepharmaletter.com/article/sk-bioscience-and-vaxxas-to-develop-needle-free-patch-delivery-of-typhoid-vaccine"  
[X Link](https://x.com/ThePharmaLetter/status/1694993994550264123)  2023-08-25T08:43Z 25.4K followers, [---] engagements


"@CARGOTx sets IPO terms https://www.thepharmaletter.com/article/cargo-therapeutics-sets-ipo-terms https://www.thepharmaletter.com/article/cargo-therapeutics-sets-ipo-terms"  
[X Link](https://x.com/ThePharmaLetter/status/1722202150837842125)  2023-11-08T10:39Z 25.4K followers, [--] engagements


"WHO Prequalification for SK biosciences typhoid conjugate vaccine https://www.thepharmaletter.com/article/who-prequalification-for-sk-bioscience-s-typhoid-conjugate-vaccine https://www.thepharmaletter.com/article/who-prequalification-for-sk-bioscience-s-typhoid-conjugate-vaccine"  
[X Link](https://x.com/ThePharmaLetter/status/1762049577010483632)  2024-02-26T09:38Z 25.4K followers, [---] engagements


"Innovent Biologics appoints new chief business officer https://www.thepharmaletter.com/article/innovent-biologics-appoints-new-chief-business-officer https://www.thepharmaletter.com/article/innovent-biologics-appoints-new-chief-business-officer"  
[X Link](https://x.com/ThePharmaLetter/status/1785580043617321043)  2024-05-01T08:00Z 25.4K followers, [---] engagements


"@athirapharma tanks as fosgonimeton misses in Alzheimers trial https://www.thepharmaletter.com/athira-pharma-tanks-as-fosgonimeton-misses-in-alzheimers-trial https://www.thepharmaletter.com/athira-pharma-tanks-as-fosgonimeton-misses-in-alzheimers-trial"  
[X Link](https://x.com/ThePharmaLetter/status/1831695815510786534)  2024-09-05T14:08Z 25.4K followers, [--] engagements


"@PeptiDream_Inc unit and @Curium_Pharma join forces on radiopharma candidates https://www.thepharmaletter.com/peptidream-unit-and-curium-join-forces-on-radiopharma-candidates https://www.thepharmaletter.com/peptidream-unit-and-curium-join-forces-on-radiopharma-candidates"  
[X Link](https://x.com/ThePharmaLetter/status/1843190843035000917)  2024-10-07T07:25Z 25.4K followers, [--] engagements


"@UpstreamBio shares soar in impressive IPO https://www.thepharmaletter.com/upstream-bio-shares-soar-in-impressive-ipo https://www.thepharmaletter.com/upstream-bio-shares-soar-in-impressive-ipo"  
[X Link](https://x.com/ThePharmaLetter/status/1845868185083408430)  2024-10-14T16:44Z 25.4K followers, [--] engagements


"Alteogen jumps as it inks licence deal with @DaiichiSankyo https://www.thepharmaletter.com/alteogen-jumps-as-it-inks-licence-deal-with-daiichi-sankyo https://www.thepharmaletter.com/alteogen-jumps-as-it-inks-licence-deal-with-daiichi-sankyo"  
[X Link](https://x.com/ThePharmaLetter/status/1855886304090730644)  2024-11-11T08:12Z 25.4K followers, [---] engagements


"SK Biopharmaceuticals cenobamate paves the way for expansion https://www.thepharmaletter.com/sk-biopharmaceuticals-cenobamate-paves-the-way-for-expansion https://www.thepharmaletter.com/sk-biopharmaceuticals-cenobamate-paves-the-way-for-expansion"  
[X Link](https://x.com/ThePharmaLetter/status/1866910411330863593)  2024-12-11T18:18Z 25.4K followers, [---] engagements


"@Synaffix out-licenses ADC technology to @elevationonc https://www.thepharmaletter.com/synaffix-out-licenses-adc-technology-to-elevation-oncology https://www.thepharmaletter.com/synaffix-out-licenses-adc-technology-to-elevation-oncology"  
[X Link](https://x.com/ThePharmaLetter/status/1867510727957000646)  2024-12-13T10:03Z 25.4K followers, [--] engagements


"@sanofi expands SK bioscience deal for pneumococcal conjugate vaccines https://www.thepharmaletter.com/sanofi-expands-sk-bioscience-deal-for-pneumococcal-conjugate-vaccines https://www.thepharmaletter.com/sanofi-expands-sk-bioscience-deal-for-pneumococcal-conjugate-vaccines"  
[X Link](https://x.com/ThePharmaLetter/status/1871482032959946940)  2024-12-24T09:04Z 25.4K followers, [--] engagements


"Keros Therapeutics drops another Phase II cibotercept trial https://www.thepharmaletter.com/keros-therapeutics-drops-another-phase-2-cibotercept-trial https://www.thepharmaletter.com/keros-therapeutics-drops-another-phase-2-cibotercept-trial"  
[X Link](https://x.com/ThePharmaLetter/status/1879811032291610713)  2025-01-16T08:40Z 25.4K followers, [---] engagements


"@AscentagePharma's sets terms for $149 million US IPO https://www.thepharmaletter.com/ascentage-pharma-sets-terms-for-149-million-dollar-us-ipo https://www.thepharmaletter.com/ascentage-pharma-sets-terms-for-149-million-dollar-us-ipo"  
[X Link](https://x.com/ThePharmaLetter/status/1882362970380071095)  2025-01-23T09:41Z 25.4K followers, [--] engagements


"@RepareRx to cut 75% of workforce in major restructuring https://www.thepharmaletter.com/biotechnology/repare-therapeutics-to-cut-75-percent-of-workforce-in-major-restructuring https://www.thepharmaletter.com/biotechnology/repare-therapeutics-to-cut-75-percent-of-workforce-in-major-restructuring"  
[X Link](https://x.com/ThePharmaLetter/status/1894785576353599848)  2025-02-26T16:24Z 25.4K followers, [--] engagements


"Alteogen tech to create subcutaneous versions of AstraZenecas cancer drugs https://www.thepharmaletter.com/alteogen-tech-to-create-subcutaneous-versions-of-astrazeneca-s-cancer-drugs https://www.thepharmaletter.com/alteogen-tech-to-create-subcutaneous-versions-of-astrazeneca-s-cancer-drugs"  
[X Link](https://x.com/ThePharmaLetter/status/1901677883816390929)  2025-03-17T16:51Z 25.4K followers, [---] engagements


"BeiGene drops development of ociperlimab https://www.thepharmaletter.com/beigene-drops-development-of-ociperlimab https://www.thepharmaletter.com/beigene-drops-development-of-ociperlimab"  
[X Link](https://x.com/ThePharmaLetter/status/1908228393914511686)  2025-04-04T18:41Z 25.4K followers, [---] engagements


"SK scores vital win in patent dispute with @moderna_tx https://www.thepharmaletter.com/biotechnology/sk-bioscience-wins-patent-dispute-against-moderna-in-korea https://www.thepharmaletter.com/biotechnology/sk-bioscience-wins-patent-dispute-against-moderna-in-korea"  
[X Link](https://x.com/ThePharmaLetter/status/1915321352359117240)  2025-04-24T08:26Z 25.4K followers, [---] engagements


"@BeiGeneGlobal posts 46% 1st-qtr sales growth bit misses consensus https://www.thepharmaletter.com/beigene-posts-46-percent-st-qtr-sales-growth-bit-misses-consensus https://www.thepharmaletter.com/beigene-posts-46-percent-st-qtr-sales-growth-bit-misses-consensus"  
[X Link](https://x.com/ThePharmaLetter/status/1920468175356834205)  2025-05-08T13:17Z 25.4K followers, [--] engagements


"KDCA and SK bioscience forge ahead to shield South Korea against pandemic influenza threats https://www.thepharmaletter.com/kdca-and-sk-bioscience-forge-ahead-to-shield-south-korea-against-pandemic-influenza-threats https://www.thepharmaletter.com/kdca-and-sk-bioscience-forge-ahead-to-shield-south-korea-against-pandemic-influenza-threats"  
[X Link](https://x.com/ThePharmaLetter/status/1927265275583373433)  2025-05-27T07:27Z 25.4K followers, [---] engagements


"@igmbio to be acquired by Concentra https://www.thepharmaletter.com/biotechnology/igm-biosciences-to-be-acquired-by-concentra https://www.thepharmaletter.com/biotechnology/igm-biosciences-to-be-acquired-by-concentra"  
[X Link](https://x.com/ThePharmaLetter/status/1940804443286515759)  2025-07-03T16:06Z 25.4K followers, [--] engagements


"@RecordatiD touts new data in Cushings syndrome https://www.thepharmaletter.com/pharmaceutical/recordati-rare-diseases-touts-new-data-incushings-syndrome https://www.thepharmaletter.com/pharmaceutical/recordati-rare-diseases-touts-new-data-incushings-syndrome"  
[X Link](https://x.com/ThePharmaLetter/status/1945044377853624625)  2025-07-15T08:54Z 25.4K followers, [--] engagements


"Delay hits @REGENXBIO BLA review https://www.thepharmaletter.com/biotechnology/delay-hits-regenxbio-bla-review https://www.thepharmaletter.com/biotechnology/delay-hits-regenxbio-bla-review"  
[X Link](https://x.com/ThePharmaLetter/status/1958438054797971495)  2025-08-21T07:56Z 25.4K followers, [---] engagements


"Q&A with Jon Congleton CEO of @Mineralystx https://www.thepharmaletter.com/pharmaceutical/q-a-with-jon-congleton-ceo-of-mineralys-therapeutics https://www.thepharmaletter.com/pharmaceutical/q-a-with-jon-congleton-ceo-of-mineralys-therapeutics"  
[X Link](https://x.com/ThePharmaLetter/status/1963337266484707372)  2025-09-03T20:24Z 25.4K followers, [---] engagements


"Alteogen wins European approval for Eylea biosimilar Eyluxvi https://www.thepharmaletter.com/biosimilars/alteogen-wins-european-approval-for-eylea-biosimilar-eyluxvi https://www.thepharmaletter.com/biosimilars/alteogen-wins-european-approval-for-eylea-biosimilar-eyluxvi"  
[X Link](https://x.com/ThePharmaLetter/status/1968938892456780272)  2025-09-19T07:23Z 25.4K followers, [---] engagements


"@Convatec to invest $1 billion+ in global R&D expansion https://www.thepharmaletter.com/pharmaceutical/convatec-to-invest-1-billion-in-globa-r-and-d-expansion https://www.thepharmaletter.com/pharmaceutical/convatec-to-invest-1-billion-in-globa-r-and-d-expansion"  
[X Link](https://x.com/ThePharmaLetter/status/1974021877627597185)  2025-10-03T08:01Z 25.4K followers, [--] engagements


"@AltoNeuro rockets on news of $50 million private placement https://www.thepharmaletter.com/pharmaceutical/alto-neuroscience-rockets-on-news-of-50-million-private-placement https://www.thepharmaletter.com/pharmaceutical/alto-neuroscience-rockets-on-news-of-50-million-private-placement"  
[X Link](https://x.com/ThePharmaLetter/status/1981062577506443344)  2025-10-22T18:18Z 25.4K followers, [--] engagements


"Kaigene inks exclusive licensing deal with @Celltrioninc https://www.thepharmaletter.com/bms-news/kaigene-inks-exclusive-licensing-deal-with-celltrion https://www.thepharmaletter.com/bms-news/kaigene-inks-exclusive-licensing-deal-with-celltrion"  
[X Link](https://x.com/ThePharmaLetter/status/1986009483538276573)  2025-11-05T09:55Z 25.4K followers, [---] engagements


"Sandoz finalizes deal to acquire Just-Evotec Biologics https://www.thepharmaletter.com/biosimilars/sandoz-finalizes-deal-to-acquire-just-evotec-biologics https://www.thepharmaletter.com/biosimilars/sandoz-finalizes-deal-to-acquire-just-evotec-biologics"  
[X Link](https://x.com/ThePharmaLetter/status/1986824668209168677)  2025-11-07T15:54Z 25.4K followers, [---] engagements


"@KymeraTx soars on positive Phase Ib Clinical trial of KT-621 https://www.thepharmaletter.com/biotechnology/kymera-soars-on-positive-phase-ib-clinical-trial-of-ky-621 https://www.thepharmaletter.com/biotechnology/kymera-soars-on-positive-phase-ib-clinical-trial-of-ky-621"  
[X Link](https://x.com/ThePharmaLetter/status/1998077834712219831)  2025-12-08T17:10Z 25.4K followers, [--] engagements


"@argenxglobal wins UK MHRA approval of Vyvgart https://www.thepharmaletter.com/biotechnology/argenx-wins-uk-mhra-approval-of--vyvgart https://www.thepharmaletter.com/biotechnology/argenx-wins-uk-mhra-approval-of--vyvgart"  
[X Link](https://x.com/ThePharmaLetter/status/2001651995674059252)  2025-12-18T13:53Z 25.4K followers, [--] engagements


"@Evotec appoints new global communications head https://www.thepharmaletter.com/biotechnology/evotec-appoints-new-global-communications-head https://www.thepharmaletter.com/biotechnology/evotec-appoints-new-global-communications-head"  
[X Link](https://x.com/ThePharmaLetter/status/2007125114639229338)  2026-01-02T16:21Z 25.4K followers, [---] engagements


"Zenas BioPharma tanks on Phase III obexelimab trial results https://www.thepharmaletter.com/biotechnology/zenas-biopharma-tanks-on--phase-iii-obexelimab-trial-results https://www.thepharmaletter.com/biotechnology/zenas-biopharma-tanks-on--phase-iii-obexelimab-trial-results"  
[X Link](https://x.com/ThePharmaLetter/status/2008204785951130051)  2026-01-05T15:51Z 25.4K followers, [---] engagements


"@argenxglobal leadership transition as CEO retires https://www.thepharmaletter.com/biotechnology/argenx-leadership-transition-as-ceo-retires https://www.thepharmaletter.com/biotechnology/argenx-leadership-transition-as-ceo-retires"  
[X Link](https://x.com/ThePharmaLetter/status/2008559190323888466)  2026-01-06T15:20Z 25.4K followers, [--] engagements


"@LonzaGroup's @Synaffix and Sidewinder collaborate on ADCs https://www.thepharmaletter.com/biotechnology/lonza-s-synaffix-and-sidewinder-collaborate-on-adcs https://www.thepharmaletter.com/biotechnology/lonza-s-synaffix-and-sidewinder-collaborate-on-adcs"  
[X Link](https://x.com/ThePharmaLetter/status/2008904617287958859)  2026-01-07T14:12Z 25.4K followers, [--] engagements


"Teva inks deal with Royalty Pharma on potential vitiligo drug https://www.thepharmaletter.com/pharma-news/teva-inks-deal-with-royalty-pharma-on-potential-vitiligo-drug https://www.thepharmaletter.com/pharma-news/teva-inks-deal-with-royalty-pharma-on-potential-vitiligo-drug"  
[X Link](https://x.com/ThePharmaLetter/status/2010716720839672088)  2026-01-12T14:13Z 25.4K followers, [---] engagements


"Sino Biopharmaceutical buys Hygieia https://www.thepharmaletter.com/biotech-news/sino-biopharmaceutical-buys-hygieia https://www.thepharmaletter.com/biotech-news/sino-biopharmaceutical-buys-hygieia"  
[X Link](https://x.com/ThePharmaLetter/status/2011356230925811950)  2026-01-14T08:34Z 25.4K followers, [---] engagements


"FDA grants Ipsens IPN60340 Breakthrough status https://www.thepharmaletter.com/pharma-news/fda-grants-ipsen-s-ipn60340-breakthrough-status https://www.thepharmaletter.com/pharma-news/fda-grants-ipsen-s-ipn60340-breakthrough-status"  
[X Link](https://x.com/ThePharmaLetter/status/2011421331817169221)  2026-01-14T12:53Z 25.4K followers, [---] engagements


"First glimpse of new @novonordisk's CEOs strategy at JP Morgan https://www.thepharmaletter.com/pharma-news/first-glimpse-of-new-novo-nordisk-ceo-s-strategy-at-jp-morgan https://www.thepharmaletter.com/pharma-news/first-glimpse-of-new-novo-nordisk-ceo-s-strategy-at-jp-morgan"  
[X Link](https://x.com/ThePharmaLetter/status/2011421445545767142)  2026-01-14T12:53Z 25.4K followers, [---] engagements


"Alteogen grants @GSKs Tesaro global rights to ALT-B4 https://www.thepharmaletter.com/biotech-news/alteogen-grants-gsks-tesaro-global-rights-to-altb4 https://www.thepharmaletter.com/biotech-news/alteogen-grants-gsks-tesaro-global-rights-to-altb4"  
[X Link](https://x.com/ThePharmaLetter/status/2013586449048711660)  2026-01-20T12:16Z 25.4K followers, [---] engagements


"@pfizer sells @ViiVHC stake to @ShionogiUS https://www.thepharmaletter.com/pharma-news/pfizer-sells-viiv-stake-to-shionogi https://www.thepharmaletter.com/pharma-news/pfizer-sells-viiv-stake-to-shionogi"  
[X Link](https://x.com/ThePharmaLetter/status/2013628397109358753)  2026-01-20T15:03Z 25.4K followers, [--] engagements


"@LonzaGroup delivers strong profitable growth in [----] https://www.thepharmaletter.com/generics-news/lonza-delivers-strong-profitable-growth-in-2025 https://www.thepharmaletter.com/generics-news/lonza-delivers-strong-profitable-growth-in-2025"  
[X Link](https://x.com/ThePharmaLetter/status/2016793224359100791)  2026-01-29T08:39Z 25.4K followers, [--] engagements


"Trade group ponders how to attract trials to Belgium https://www.thepharmaletter.com/pharma-news/trade-group-ponders-how-to-attract-trials-to-belgium https://www.thepharmaletter.com/pharma-news/trade-group-ponders-how-to-attract-trials-to-belgium"  
[X Link](https://x.com/ThePharmaLetter/status/2018608814258352538)  2026-02-03T08:53Z 25.4K followers, [--] engagements


"@KaziaTx advances nuclear PD-L1 degrader with pre-clinical data https://www.thepharmaletter.com/biotech-news/kazia-advances-nuclear-pdl1-degrader-with-pre-clinical-data https://www.thepharmaletter.com/biotech-news/kazia-advances-nuclear-pdl1-degrader-with-pre-clinical-data"  
[X Link](https://x.com/ThePharmaLetter/status/2018609295307472944)  2026-02-03T08:55Z 25.4K followers, [--] engagements


"SK bioscience in-licenses RSV preventive antibody from Gates MRI https://www.thepharmaletter.com/biotech-news/sk-bioscience-inlicenses-rsv-preventive-antibody-from-gates-mri https://www.thepharmaletter.com/biotech-news/sk-bioscience-inlicenses-rsv-preventive-antibody-from-gates-mri"  
[X Link](https://x.com/ThePharmaLetter/status/2018685745385398766)  2026-02-03T13:59Z 25.4K followers, [---] engagements


"FDA issues CRL on @AstraZenecas Saphnelo BLA https://www.thepharmaletter.com/biotech-news/fda-issues-crl-on-astrazeneca-s-saphnelo-bla https://www.thepharmaletter.com/biotech-news/fda-issues-crl-on-astrazeneca-s-saphnelo-bla"  
[X Link](https://x.com/ThePharmaLetter/status/2018686350036258887)  2026-02-03T14:01Z 25.4K followers, [---] engagements


"@Merck beats estimates but cautious on [----] https://www.thepharmaletter.com/pharma-news/merck-co-beats-estimates-but-cautious-on-2026 https://www.thepharmaletter.com/pharma-news/merck-co-beats-estimates-but-cautious-on-2026"  
[X Link](https://x.com/ThePharmaLetter/status/2019005714107367624)  2026-02-04T11:10Z 25.4K followers, [--] engagements


"TIGIT blockers tipped for growth despite rocky record https://www.thepharmaletter.com/pharma-news/tigit-blockers-tipped-for-growth-despite-rocky-record https://www.thepharmaletter.com/pharma-news/tigit-blockers-tipped-for-growth-despite-rocky-record"  
[X Link](https://x.com/ThePharmaLetter/status/2019077458520051746)  2026-02-04T15:55Z 25.4K followers, [--] engagements


"States widen generics antitrust case to Novartis in new filing https://www.thepharmaletter.com/generics-news/states-widen-generics-antitrust-case-to-novartis-in-new-filing https://www.thepharmaletter.com/generics-news/states-widen-generics-antitrust-case-to-novartis-in-new-filing"  
[X Link](https://x.com/ThePharmaLetter/status/2019077650044662245)  2026-02-04T15:56Z 25.4K followers, [---] engagements


"@Novartis delivered high single-digit sales growth in [----] https://www.thepharmaletter.com/pharma-news/novartis-delivered-high-single-digit-sales-growth-in-2025 https://www.thepharmaletter.com/pharma-news/novartis-delivered-high-single-digit-sales-growth-in-2025"  
[X Link](https://x.com/ThePharmaLetter/status/2019122093246259330)  2026-02-04T18:53Z 25.4K followers, [--] engagements


"@novonordisk tanks on financial guidance https://www.thepharmaletter.com/pharma-news/novo-nordisk-tanks-on-financial-guidance https://www.thepharmaletter.com/pharma-news/novo-nordisk-tanks-on-financial-guidance"  
[X Link](https://x.com/ThePharmaLetter/status/2019122653504893064)  2026-02-04T18:55Z 25.4K followers, [--] engagements


"Forecast-topping @EliLillyandCo leaves Novo Nordisk in the shade https://www.thepharmaletter.com/pharma-news/forecast-topping-lilly-leaves-novo-nordisk-in-the-shade https://www.thepharmaletter.com/pharma-news/forecast-topping-lilly-leaves-novo-nordisk-in-the-shade"  
[X Link](https://x.com/ThePharmaLetter/status/2019122723553976462)  2026-02-04T18:55Z 25.4K followers, [---] engagements


"Third Arc Bio closes $52 million Series A extension https://www.thepharmaletter.com/biotech-news/third-arc-bio-closes-52-million-series-a-extension https://www.thepharmaletter.com/biotech-news/third-arc-bio-closes-52-million-series-a-extension"  
[X Link](https://x.com/ThePharmaLetter/status/2019122999396581601)  2026-02-04T18:56Z 25.4K followers, [---] engagements


"@veradermics announces pricing of upsized IPO #VeraDermics #IPO #BiotechIPO #IPOPricing #Nasdaq #Biotech #PharmaNews #HealthcareInvesting #CapitalMarkets #PublicOffering #StockMarket #Investing #Dermatology #Biopharma #WallStreet https://www.thepharmaletter.com/biotech-news/veradermics-announces-pricing-of-upsized-ipo https://www.thepharmaletter.com/biotech-news/veradermics-announces-pricing-of-upsized-ipo"  
[X Link](https://x.com/ThePharmaLetter/status/2019477976266477635)  2026-02-05T18:27Z 25.4K followers, [--] engagements


"Sobi reports 4th-qrt and full year [----] results #Sobi #SOBI #FY2025 #Q4Results #Earnings #Biopharma #RareDiseases #FinancialResults #Stockholm #PharmaNews #HealthcareInvesting #InvestorRelations #NasdaqStockholm #HealthcareFinance #PharmaIndustry https://www.thepharmaletter.com/biotech-news/sobi-reports-4th-qrt-and-full-year-2025-results https://www.thepharmaletter.com/biotech-news/sobi-reports-4th-qrt-and-full-year-2025-results"  
[X Link](https://x.com/ThePharmaLetter/status/2019478192872976564)  2026-02-05T18:28Z 25.4K followers, [--] engagements


"@novonordisk appoints new head of its US business #NovoNordisk #Leadership #USBusiness #PharmaNews #Healthcare #Biopharma #Executive #USMarket #PharmaIndustry #Innovation #GlobalHealthcare https://www.thepharmaletter.com/pharma-news/novo-nordisk-appoints-new-head-of-its-us-business https://www.thepharmaletter.com/pharma-news/novo-nordisk-appoints-new-head-of-its-us-business"  
[X Link](https://x.com/ThePharmaLetter/status/2019478714824740958)  2026-02-05T18:30Z 25.4K followers, [--] engagements


"Braveheart Bio names Marc Evanchik CSO https://www.thepharmaletter.com/biotech-news/braveheart-bio-names-marc-evanchik-cso https://www.thepharmaletter.com/biotech-news/braveheart-bio-names-marc-evanchik-cso"  
[X Link](https://x.com/ThePharmaLetter/status/2019806607081984119)  2026-02-06T16:13Z 25.4K followers, [--] engagements


"SVF Vaccines to take over Novakand in reverse acquisition https://www.thepharmaletter.com/pharma-news/svf-vaccines-to-take-over-novakand-in-reverse-acquisition https://www.thepharmaletter.com/pharma-news/svf-vaccines-to-take-over-novakand-in-reverse-acquisition"  
[X Link](https://x.com/ThePharmaLetter/status/2019806773499306409)  2026-02-06T16:13Z 25.4K followers, [--] engagements


"Novo Nordisk to sue Hims & Hers over illegal compounding https://www.thepharmaletter.com/generics-news/novo-nordisk-to-sue-hims-and-hers-over-illegal-compounding https://www.thepharmaletter.com/generics-news/novo-nordisk-to-sue-hims-and-hers-over-illegal-compounding"  
[X Link](https://x.com/ThePharmaLetter/status/2019806865585230265)  2026-02-06T16:14Z 25.4K followers, [---] engagements


"Celgene partners with UK's Oxford Sciences Innovation @Celgene #pharma http://bit.ly/TPL-Celgene-OSI http://bit.ly/TPL-Celgene-OSI"  
[X Link](https://x.com/ThePharmaLetter/status/819600423434723329)  2017-01-12T17:42Z 25.4K followers, [--] engagements


"Celgene partners with UK's Oxford Sciences Innovation #pharma @Celgene http://bit.ly/TPL-Celgene-OSI http://bit.ly/TPL-Celgene-OSI"  
[X Link](https://x.com/ThePharmaLetter/status/819665766878478337)  2017-01-12T22:02Z 25.4K followers, [--] engagements


". @Genmab jumps powered by more positive Darzalex data @JanssenGlobal @JNJNews #biotech https://www.thepharmaletter.com/article/genmab-jumps-powered-by-more-positive-darzalex-data https://www.thepharmaletter.com/article/genmab-jumps-powered-by-more-positive-darzalex-data"  
[X Link](https://x.com/ThePharmaLetter/status/1057320092910972935)  2018-10-30T17:15Z 25.3K followers, [--] engagements


"Board changes planned at @VertexPharma #pharma #rarediseases #respiratory #pulmonary #USA https://www.thepharmaletter.com/article/board-changes-planned-at-vertex-pharma https://www.thepharmaletter.com/article/board-changes-planned-at-vertex-pharma"  
[X Link](https://x.com/ThePharmaLetter/status/1154683903137013760)  2019-07-26T09:24Z 25.3K followers, [--] engagements


"Transgene and SillaJen drop Pexa-Vec study due to futility #biotech https://www.thepharmaletter.com/article/transgene-and-sillajen-drop-pexa-vec-study-due-to-futility https://www.thepharmaletter.com/article/transgene-and-sillajen-drop-pexa-vec-study-due-to-futility"  
[X Link](https://x.com/ThePharmaLetter/status/1157324690714693632)  2019-08-02T16:18Z 25.3K followers, [--] engagements


".@US_FDA approves Oxlumo first drug to treat rare metabolic disorder https://www.thepharmaletter.com/article/fda-approves-oxlumo-first-drug-to-treat-rare-metabolic-disorder https://www.thepharmaletter.com/article/fda-approves-oxlumo-first-drug-to-treat-rare-metabolic-disorder"  
[X Link](https://x.com/ThePharmaLetter/status/1331193662974332928)  2020-11-24T11:11Z 25.3K followers, [--] engagements


"@GileadSciences to acquire @Miro_Bio https://www.thepharmaletter.com/article/gilead-sciences-to-acquire-mirobio https://www.thepharmaletter.com/article/gilead-sciences-to-acquire-mirobio"  
[X Link](https://x.com/ThePharmaLetter/status/1555202297315082241)  2022-08-04T14:41Z 25.3K followers, [--] engagements


"@grunenthalgroup to license osteoarthritis pain treatment to @SHIONOGI_JP https://www.thepharmaletter.com/article/grunenthal-to-license-osteoarthritis-pain-treatment-to-shionogi https://www.thepharmaletter.com/article/grunenthal-to-license-osteoarthritis-pain-treatment-to-shionogi"  
[X Link](https://x.com/ThePharmaLetter/status/1555252372875747328)  2022-08-04T18:00Z 25.3K followers, [--] engagements


"Promising new data for @ShionogiGI's S-217622 a therapeutic drug for #COVID19 https://www.thepharmaletter.com/article/promising-new-data-for-shionogi-s-s-217622-a-therapeutic-drug-for-covid-19 https://www.thepharmaletter.com/article/promising-new-data-for-shionogi-s-s-217622-a-therapeutic-drug-for-covid-19"  
[X Link](https://x.com/ThePharmaLetter/status/1557364172542853120)  2022-08-10T13:52Z 25.3K followers, [--] engagements


"@Sandoz_Global's biosimilar of denosumab Phase I/III clinical trial https://www.thepharmaletter.com/article/sandoz-biosimilar-of-denosumab-phase-i-iii-clinical-trial https://www.thepharmaletter.com/article/sandoz-biosimilar-of-denosumab-phase-i-iii-clinical-trial"  
[X Link](https://x.com/ThePharmaLetter/status/1572147541092737024)  2022-09-20T08:55Z 25.3K followers, [--] engagements


"EC approval for @amicusrx1's Pombiliti https://www.thepharmaletter.com/article/ec-approval-for-amicus-pombiliti https://www.thepharmaletter.com/article/ec-approval-for-amicus-pombiliti"  
[X Link](https://x.com/ThePharmaLetter/status/1640687774134042628)  2023-03-28T12:10Z 25.3K followers, [---] engagements


"KSQ Therapeutics bags deal with Roche for clinical-stage USP1 Inhibitor https://www.thepharmaletter.com/article/ksq-therapeutics-bags-deal-with-roche-for-clinical-stage-usp1-inhibitor https://www.thepharmaletter.com/article/ksq-therapeutics-bags-deal-with-roche-for-clinical-stage-usp1-inhibitor"  
[X Link](https://x.com/ThePharmaLetter/status/1680870398810894338)  2023-07-17T09:21Z 25.3K followers, [---] engagements


"Treatment with VX-548 led to statistically-significant improvement in pain https://www.thepharmaletter.com/article/treatment-with-vx-548-led-to-statistically-significant-improvement-in-pain https://www.thepharmaletter.com/article/treatment-with-vx-548-led-to-statistically-significant-improvement-in-pain"  
[X Link](https://x.com/ThePharmaLetter/status/1752637345298288666)  2024-01-31T10:18Z 25.3K followers, [---] engagements


"Sosei Group renamed @NxeraPharma https://www.thepharmaletter.com/article/sosei-group-renamed-nxera-pharma https://www.thepharmaletter.com/article/sosei-group-renamed-nxera-pharma"  
[X Link](https://x.com/ThePharmaLetter/status/1775218038528147803)  2024-04-02T17:45Z 25.3K followers, [---] engagements


"@NxeraPharma partners with Handok for Pivlaz distribution https://www.thepharmaletter.com/article/nxera-partners-with-handok-for-pivlaz-distribution https://www.thepharmaletter.com/article/nxera-partners-with-handok-for-pivlaz-distribution"  
[X Link](https://x.com/ThePharmaLetter/status/1780148535494684693)  2024-04-16T08:17Z 25.3K followers, [--] engagements


"@VertexPharma updates on suzetrigine (VX-548) in acute and neuropathic pain https://www.thepharmaletter.com/article/vertex-updates-on-suzetrigine-vx-548-in-acute-and-neuropathic-pain https://www.thepharmaletter.com/article/vertex-updates-on-suzetrigine-vx-548-in-acute-and-neuropathic-pain"  
[X Link](https://x.com/ThePharmaLetter/status/1781314487540240568)  2024-04-19T13:30Z 25.3K followers, [---] engagements


"@DareBioscience raises $22 million by licensing royalties https://www.thepharmaletter.com/article/dare-bioscience-raises-22-million-by-licensing-royalties https://www.thepharmaletter.com/article/dare-bioscience-raises-22-million-by-licensing-royalties"  
[X Link](https://x.com/ThePharmaLetter/status/1786115637242188011)  2024-05-02T19:28Z 25.3K followers, [--] engagements


"@NxeraPharma and @precisionlifeAI expand R&D partnership into new area https://www.thepharmaletter.com/article/nxera-pharma-and-precisionlife-expand-r-d-partnership-into-new-area https://www.thepharmaletter.com/article/nxera-pharma-and-precisionlife-expand-r-d-partnership-into-new-area"  
[X Link](https://x.com/ThePharmaLetter/status/1796457817345507413)  2024-05-31T08:24Z 25.3K followers, [--] engagements


"Change at the top for @REGENXBIO https://www.thepharmaletter.com/article/change-at-the-top-for-regenxbio https://www.thepharmaletter.com/article/change-at-the-top-for-regenxbio"  
[X Link](https://x.com/ThePharmaLetter/status/1801175317567897982)  2024-06-13T08:50Z 25.3K followers, [---] engagements


"New data on @SHIONOGI_JP's COVID-19 treatment ensitrelvir https://www.thepharmaletter.com/new-data-on-shionogio-covid-19-treatmen-ensitrelvir https://www.thepharmaletter.com/new-data-on-shionogio-covid-19-treatmen-ensitrelvir"  
[X Link](https://x.com/ThePharmaLetter/status/1808143249753751879)  2024-07-02T14:18Z 25.3K followers, [---] engagements


"FDA approves @AscendisPharma's Yorvipath https://www.thepharmaletter.com/fda-approves-yorvipath https://www.thepharmaletter.com/fda-approves-yorvipath"  
[X Link](https://x.com/ThePharmaLetter/status/1823277468955848740)  2024-08-13T08:36Z 25.3K followers, [---] engagements


"Positive top-line results for @Incytes Monjuvi in FL https://www.thepharmaletter.com/positive-top-line-results-for-incytes-monjuvi-in-fl https://www.thepharmaletter.com/positive-top-line-results-for-incytes-monjuvi-in-fl"  
[X Link](https://x.com/ThePharmaLetter/status/1825456424115130738)  2024-08-19T08:55Z 25.3K followers, [---] engagements


"@NxeraPharma to receive $35 million from @neurocrine https://www.thepharmaletter.com/nxera-pharma-to-receive-35-million-doollars-from-neurocrine https://www.thepharmaletter.com/nxera-pharma-to-receive-35-million-doollars-from-neurocrine"  
[X Link](https://x.com/ThePharmaLetter/status/1830944310449041546)  2024-09-03T12:21Z 25.3K followers, [--] engagements


"Full FDA approval for @TravereRare's Filspari https://www.thepharmaletter.com/full-fda-approval-for-traveres-filspari https://www.thepharmaletter.com/full-fda-approval-for-traveres-filspari"  
[X Link](https://x.com/ThePharmaLetter/status/1833064117310996581)  2024-09-09T08:45Z 25.3K followers, [---] engagements


"@ProKidney updates on rilparencels registrational path to potential US approval https://www.thepharmaletter.com/prokidney-updates-on-rilparencel-registrational-path-to-potential-us-approval https://www.thepharmaletter.com/prokidney-updates-on-rilparencel-registrational-path-to-potential-us-approval"  
[X Link](https://x.com/ThePharmaLetter/status/1833418701153927599)  2024-09-10T08:14Z 25.3K followers, [--] engagements


"@NxeraPharma's Quviviq approved in Japan for insomnia https://www.thepharmaletter.com/nxera-pharmas-quviviq-approved-in-japan-for-insomnia https://www.thepharmaletter.com/nxera-pharmas-quviviq-approved-in-japan-for-insomnia"  
[X Link](https://x.com/ThePharmaLetter/status/1838857616983814381)  2024-09-25T08:26Z 25.3K followers, [--] engagements


"@AstraZeneca boosts cardiovascular pipeline via deal with CSPC https://www.thepharmaletter.com/astrazeneca-boosts-cardiovascular-pipeline-via-deal-with-cspc https://www.thepharmaletter.com/astrazeneca-boosts-cardiovascular-pipeline-via-deal-with-cspc"  
[X Link](https://x.com/ThePharmaLetter/status/1843572344301990166)  2024-10-08T08:41Z 25.3K followers, [--] engagements


"Showing of strength of @AstraZenecas Airsupra in asthma https://www.thepharmaletter.com/showing-of-strength-of-astrazenecas-airsupra-in-asthma https://www.thepharmaletter.com/showing-of-strength-of-astrazenecas-airsupra-in-asthma"  
[X Link](https://x.com/ThePharmaLetter/status/1843572463550013615)  2024-10-08T08:41Z 25.3K followers, [---] engagements


"@TransgeneSA cancer vaccine TG4001 trial misses main goal https://www.thepharmaletter.com/transgene-cancer-vaccine-tg4001-trial-misses-main-goal https://www.thepharmaletter.com/transgene-cancer-vaccine-tg4001-trial-misses-main-goal"  
[X Link](https://x.com/ThePharmaLetter/status/1845867568348754198)  2024-10-14T16:41Z 25.3K followers, [--] engagements


"@DiscMedicine leaps as it gets positive FDA feedback https://www.thepharmaletter.com/disc-medicine-leaps-as-it-gets-positive-fda-feedback https://www.thepharmaletter.com/disc-medicine-leaps-as-it-gets-positive-fda-feedback"  
[X Link](https://x.com/ThePharmaLetter/status/1853875239186563388)  2024-11-05T19:01Z 25.3K followers, [--] engagements


"@NxeraPharma and @AntiverseHQ partner on GPCRs https://www.thepharmaletter.com/nxera-pharma-and-antiverse-partner-on-gpcrs https://www.thepharmaletter.com/nxera-pharma-and-antiverse-partner-on-gpcrs"  
[X Link](https://x.com/ThePharmaLetter/status/1853876770459791843)  2024-11-05T19:07Z 25.3K followers, [--] engagements


"@TransgeneSA and @probiogen join forces on cancer vaccines https://www.thepharmaletter.com/transgene-and-probiogen-join-forces-on-cancer-vaccines https://www.thepharmaletter.com/transgene-and-probiogen-join-forces-on-cancer-vaccines"  
[X Link](https://x.com/ThePharmaLetter/status/1853876919692922919)  2024-11-05T19:07Z 25.3K followers, [--] engagements


"EC approval for @Sandoz_Global's Afqlir https://www.thepharmaletter.com/ec-approval-for-sandoz-afqlir https://www.thepharmaletter.com/ec-approval-for-sandoz-afqlir"  
[X Link](https://x.com/ThePharmaLetter/status/1858527473819898010)  2024-11-18T15:07Z 25.3K followers, [---] engagements


"MHRA approves Filspari for IgAN https://www.thepharmaletter.com/mhra-approves-filspari-for-igan https://www.thepharmaletter.com/mhra-approves-filspari-for-igan"  
[X Link](https://x.com/ThePharmaLetter/status/1859184846368604672)  2024-11-20T10:39Z 25.3K followers, [---] engagements


"FDA priority review for Nuvation Bio's taletrectinib https://www.thepharmaletter.com/fda-priority-review-for-nuvation-bios-taletrectinib https://www.thepharmaletter.com/fda-priority-review-for-nuvation-bios-taletrectinib"  
[X Link](https://x.com/ThePharmaLetter/status/1871482826622931155)  2024-12-24T09:07Z 25.3K followers, [---] engagements


"@REGENXBIO inks MPS drugs collab with @nipponshinyaku https://www.thepharmaletter.com/regenxbio-inks-mps-drugs-collab-with-nippon-shinyaku https://www.thepharmaletter.com/regenxbio-inks-mps-drugs-collab-with-nippon-shinyaku"  
[X Link](https://x.com/ThePharmaLetter/status/1879810109930639626)  2025-01-16T08:37Z 25.3K followers, [--] engagements


"AB2 Bio signs US licensing deal with @nipponshinyaku for tadekinig alfa https://www.thepharmaletter.com/ab2-bio-signs-us-licensing-deal-with-nippon-shinyaku-for-tadekinig-alfa https://www.thepharmaletter.com/ab2-bio-signs-us-licensing-deal-with-nippon-shinyaku-for-tadekinig-alfa"  
[X Link](https://x.com/ThePharmaLetter/status/1884280726922887540)  2025-01-28T16:41Z 25.3K followers, [---] engagements


"Bambusa Therapeutics raises $90 million in Series A Financing https://www.thepharmaletter.com/bambusa-therapeutics-raises-90-million-dollars-in-series-a-financing https://www.thepharmaletter.com/bambusa-therapeutics-raises-90-million-dollars-in-series-a-financing"  
[X Link](https://x.com/ThePharmaLetter/status/1891785545568698749)  2025-02-18T09:43Z 24.8K followers, [---] engagements


"@galderma doubles up on Nemluvio approvals https://www.thepharmaletter.com/galderma-doubles-up-on-nemluvio-approvals https://www.thepharmaletter.com/galderma-doubles-up-on-nemluvio-approvals"  
[X Link](https://x.com/ThePharmaLetter/status/1892496704575873534)  2025-02-20T08:49Z 24.8K followers, [--] engagements


"@novonordisk sues KBP over claim it was misled into deal https://www.thepharmaletter.com/novo-nordisk-sues-kbp-over-claim-it-was-misled-into-deal https://www.thepharmaletter.com/novo-nordisk-sues-kbp-over-claim-it-was-misled-into-deal"  
[X Link](https://x.com/ThePharmaLetter/status/1892498420809531558)  2025-02-20T08:55Z 24.8K followers, [--] engagements


"@Sandoz_Global launches biosimilar Pyzchiva in USA https://www.thepharmaletter.com/sandoz-launches-biosimilar-pyzchiva-in-usa https://www.thepharmaletter.com/sandoz-launches-biosimilar-pyzchiva-in-usa"  
[X Link](https://x.com/ThePharmaLetter/status/1894777719038132577)  2025-02-26T15:53Z 24.8K followers, [--] engagements


"Regenxbios RGX-202 continues to show promise in DMD https://www.thepharmaletter.com/regenxbio-s-rgx-202-continues-to-show-promise-in-dmd https://www.thepharmaletter.com/regenxbio-s-rgx-202-continues-to-show-promise-in-dmd"  
[X Link](https://x.com/ThePharmaLetter/status/1903029205148824030)  2025-03-21T10:21Z 25.3K followers, [---] engagements


"@NxeraPharma announces leadership team changes https://www.thepharmaletter.com/nxera-pharma-announces-leadership-team-changes https://www.thepharmaletter.com/nxera-pharma-announces-leadership-team-changes"  
[X Link](https://x.com/ThePharmaLetter/status/1907112294347071899)  2025-04-01T16:46Z 25.3K followers, [--] engagements


"@TransgeneSA appoints Simone Steiner as chief technical officer https://www.thepharmaletter.com/biotechnology/transgene-appoints-simone-steiner-as-chief-technical-officer https://www.thepharmaletter.com/biotechnology/transgene-appoints-simone-steiner-as-chief-technical-officer"  
[X Link](https://x.com/ThePharmaLetter/status/1907711911329755501)  2025-04-03T08:28Z 25.3K followers, [--] engagements


"@ZymeworksInc appoints new clinical development head https://www.thepharmaletter.com/biotechnology/zymeworks-appoints-new-clinical-development-head https://www.thepharmaletter.com/biotechnology/zymeworks-appoints-new-clinical-development-head"  
[X Link](https://x.com/ThePharmaLetter/status/1915312180741685633)  2025-04-24T07:49Z 25.3K followers, [--] engagements


"@PTCBio shares fall after Huntingtons study update https://www.thepharmaletter.com/ptc-therapeutics-shares-fall-after-huntingtons-study-update https://www.thepharmaletter.com/ptc-therapeutics-shares-fall-after-huntingtons-study-update"  
[X Link](https://x.com/ThePharmaLetter/status/1920027351594738005)  2025-05-07T08:06Z 25.3K followers, [--] engagements


"@NxeraPharma earns $15 million as @neurocrine advances schizophrenia drug https://www.thepharmaletter.com/pharmaceutical/nxera-milestone-neurocrine-advances https://www.thepharmaletter.com/pharmaceutical/nxera-milestone-neurocrine-advances"  
[X Link](https://x.com/ThePharmaLetter/status/1930602009436012582)  2025-06-05T12:26Z 25.3K followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing